American Bio Medica

American Bio Medica FCF Yield

Delisted

The Free Cash Flow Yield of American Bio Medica (ABMC) as of Nov 20, 2026 is -1.60 M %. In the previous year, Free Cash Flow Yield was -1.40 M % — a change of 14.12% (lower).

FCF Yield

-1.60 M %

YoY

14.12%

Last updated:

Free Cash Flow Yield of American Bio Medica is 2022 -1.60 M % . Free Cash Flow Yield of American Bio Medica was 2021 -1.40 M % . It decreases by 14.12% lower compared to the previous year.

The American Bio Medica FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2015
434,524.99 USD
Jan 1, 2016
438,683.12 USD
Jan 1, 2017
243,250.83 USD
Jan 1, 2018
-503,134.19 USD
Jan 1, 2019
120,585.88 USD
Jan 1, 2020
-1.01 M USD
Jan 1, 2021
-1.40 M USD
Jan 1, 2022
-1.60 M USD
The American Bio Medica FCF Yield history
YEARFCF YieldYoY
-1.60 M %+14.12%
-1.40 M %+38.19%
-1.01 M %-939.66%
120,585.88 %-123.97%
-503,134.19 %-306.84%
243,250.83 %-44.55%
438,683.12 %+0.96%
434,524.99 %+808.70%
47,818.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

American Bio Medica Stock analysis

What does American Bio Medica do? American Bio Medica Corp is a US-based company specializing in the development and manufacture of drug testing devices and diagnostic products. The company was founded in 1986 and is headquartered in Kinderhook, New York. Its business model involves developing and producing drug testing devices and diagnostic products used by government agencies, companies, and private customers worldwide. The company also operates a laboratory that conducts diagnostic tests for third parties. Its five business areas include drug tests, medication safety, diagnostics, biometrics, and forensics. The company's products include urine, saliva, and sweat drug tests, as well as medical devices to prevent prescription drug abuse and diagnostic products for various diseases. It also offers biometric instruments and systems for person identification and forensic products for crime investigation. American Bio Medica Corp has been publicly traded since 1992 and has received several awards for its products and innovations. The company is committed to research and development, quality assurance, and accuracy in its products. Overall, it is a leading company in the field of drug testing devices and diagnostic products and is expected to continue to evolve in the future. American Bio Medica is one of the most popular companies on Eulerpool.

Frequently Asked Questions about American Bio Medica stock

Free Cash Flow Yield of American Bio Medica is -1.60 M % in 2022.

Free Cash Flow Yield of American Bio Medica changed from -1.40 M % to -1.60 M %, representing a 14.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield American Bio Medica since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's American Bio Medica with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — American Bio Medica

All Key Metrics — American Bio Medica